BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase ...
Vertex Pharmaceuticals IncorporatedVRTX announced that two phase III studies evaluating its next-generation CFTR corrector, VX-445 in combination with tezacaftor and Kalydeco (ivacaftor) met the ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a ...
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has lifted the clinical hold placed on the phase I/II study evaluating its investigational stem cell-based therapy, VX-880, for the ...
The ongoing Phase I/II clinical trial is assessing VX-880 for the treatment of type 1 diabetes (T1D). Credit: Ahmet Misirligul/Shutterstock. Vertex Pharmaceuticals has presented positive data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback